

CHAPTER 2

Methods for Removing the Fmoc Group

Gregg B. Fields

1. Introduction

The electron withdrawing fluorene ring system of the 9-fluorenylmethoxycarbonyl (Fmoc) group renders the lone hydrogen on the β -carbon very acidic and, therefore, susceptible to removal by weak bases (1,2). Following the abstraction of this acidic proton at the 9-position of the fluorene ring system, β -elimination proceeds to give a highly reactive dibenzofulvene intermediate (1-5). Dibenzofulvene can be trapped by excess amine cleavage agents to form stable adducts (1,2). The stability of the Fmoc group to a variety of bases (6-10) is reported in Table 1. The Fmoc group is, in general, rapidly removed by primary (i.e., cyclohexylamine, ethanolamine) and some secondary (i.e., piperidine, piperazine) amines, and slowly removed by tertiary (i.e., triethylamine [Et₃N], *N,N*-diisopropylethylamine [DIEA]) amines. Removal also occurs more rapidly in a relatively polar medium (*N,N*-dimethylformamide [DMF] or *N*-methylpyrrolidone [NMP]) compared to a relatively nonpolar one (dichloromethane [DCM]). During solid-phase peptide synthesis (SPPS), the Fmoc group is removed typically with piperidine, which in turn scavenges the liberated dibenzofulvene to form a fulvene-piperidine adduct. Standard conditions for removal include 30% piperidine-DMF for 10 min (11), 20% piperidine-DMF for 10 min (12,13), 55% piperidine-DMF for 20 min (14), 30% piperidine in toluene-DMF (1:1) for 11 min (11,15-17), 23% piperidine-NMP for 10 min (9), and 20% piperidine-NMP for 18 min (18). Piperidine-DCM should not be utilized, since an amine salt precipitates after relatively brief stand-

From: *Methods in Molecular Biology, Vol 35 Peptide Synthesis Protocols*
Edited by M W Pennington and B. M. Dunn Copyright ©1994 Humana Press Inc , Totowa, NJ

Table 1
Removal of the Fmoc Group

Compound	Base	Solvent	Time, min	Deprotection, %	Reference
Fmoc-Gly-PS	10% Morpholine	DCM	240	18 ^a	6
Fmoc-Gly-PS	10% Morpholine	DMF	240	75 ^a	6
Fmoc-Gly-PS	50% Morpholine	DCM	240	100 ^a	6
Fmoc-Val	50% Morpholine	DMF	1	50 ^b	7
Fmoc-Ala-OtBu	50% Morpholine	DCM	120	100 ^c	8
Fmoc-Gly-PS	10% Piperidine	DCM	240	100 ^a	6
Fmoc-Val	20% Piperidine	DMF	0.1	50 ^b	7
Fmoc-Gly-HMP-PS	23% Piperidine	NMP	0.25	50 ^d	9
Fmoc-Ala-OtBu	50% Piperidine	DCM	<5	100 ^c	8
Fmoc-Val	5% Piperazine	DMF	0.33	50 ^b	7
Fmoc-Ala-OtBu	50% Piperazine	DCM	60	100 ^c	8
Fmoc-PCA	59% 1,4-bis-(3-aminopropyl)piperazine	CDCl ₃	2	100 ^e	10
Fmoc-Val	50% Dicyclohexylamine	DMF	35	50 ^b	7
Fmoc-Ala-OtBu	50% Dicyclohexylamine	DCM	>1080	100 ^c	8
Fmoc-Val	50% DIEA	DMF	606	50 ^b	7
Fmoc-Ala-OtBu	50% DIEA	DCM	>1080	100 ^c	8

Fmoc-Ala-O <i>t</i> Bu	50% DBU	DCM	<5	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Pyrrolidine	DCM	<5	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Cyclohexylamine	DCM	<5	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Ethanolamine	DCM	<5	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Diethylamine	DCM	180	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Triethylamine	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Ammonia	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	50% Tributylamine	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	1.0 mM triethylenediamine	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	1.0 mM Hydroxylamine HCl	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	0.5 mmol Proton sponge	DCM	>1080	100 ^c	8
Fmoc-Ala-O <i>t</i> Bu	2.0 mmol NaOH	30% CH ₃ OH- <i>p</i> -dioxane	<5	100 ^c	8
Fmoc-PCA	50% Tris(2-aminoethyl)amine	CDCl ₃	2	100 ^e	10
Fmoc-PCA	59% 1,3-Cyclohexanebis-(methylamine)	CDCl ₃	2	100 ^e	10

^aDeprotection of Fmoc-Gly-PS was quantitated spectrophotometrically at 273 nm (6)

^bDeprotection of Fmoc-Val was quantitated by amino acid analysis (7)

^cDeprotection of Fmoc-Ala-O*t*Bu was quantitated by thin-layer chromatography (8)

^dDeprotection of Fmoc-Gly-HMP-PS was quantitated by ninhydrin analysis (9).

^eDeprotection of 9-fluorenylmethyl *N*-*p*-chlorophenyl carbamate (Fmoc-PCA) was quantitated by ¹H-NMR (10). Dibenzofulvene was scavenged in 2 min by tris(2-aminoethyl)amine, 15 min by 1,3-cyclohexanebis-(methylamine), and 50 min by 1,4-bis-(3-aminopropyl)piperazine.

ing (11). An inexpensive alternative to piperidine for Fmoc removal is diethylamine, with standard conditions being 60% diethylamine-DMF for 180 min (19,20) or 10% diethylamine-*N,N*-dimethylacetamide (DMA) for 120 min (21,22).

2. Monitoring

Fmoc removal can be monitored spectrophotometrically because of the formation of dibenzofulvene or fulvene-piperidine adducts. Monitoring is especially valuable in “difficult” sequences, where Fmoc removal may be slow or incomplete (17,23,24). Slow deprotection has been correlated to a broad fulvene-piperidine peak detected at 312 nm (24–26). Monitoring of a broad fulvene-piperidine peak at 365 nm has been used to demonstrate slow deprotection from Fmoc-(Ala)₅-Val-4-hydroxymethylphenoxy (HMP)-copoly(styrene-1%-divinylbenzene)-resin (PS); in turn, detection of a narrow fulvene-piperidine peak demonstrated efficient deprotection of the same sequence on a different solid support (HMP-polyethylene glycol-PS) (27). Monitoring of fulvene-piperidine at 313 nm was utilized during the successful synthesis of the entire 76-residue sequence of ubiquitin (28). Dibenzofulvene formation has been monitored at 270 or 304 nm (29).

3. Side Reactions

Repetitive piperidine treatments can result in a number of deleterious side reactions, such as diketopiperazine and aspartimide formation and racemization of esterified Cys derivatives. Base-catalyzed cyclization of resin-bound dipeptides to diketopiperazines is especially prominent in sequences containing Pro, Gly, D-amino acids, or *N*-methyl amino acids. For continuous-flow Fmoc SPPS, diketopiperazine formation is suppressed by deprotecting for 1.5 min with 20% piperidine-DMF at an increased flow rate (15 mL/min), washing for 3 min with DMF at the same flow rate, and coupling the third Fmoc-amino acid *in situ* with benzotriazolyl *N*-oxytrisdimethylaminophosphonium hexafluorophosphate (BOP), 4-methylmorpholine, and 1-hydroxybenzotriazole (HOBT) in DMF (30). For batch-wise SPPS, rapid (a maximum of 5 min) treatments by 50% piperidine-DMF should be used, followed by DMF washes and then *in situ* acylations mediated by BOP or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (31). Piperidine catalysis of aspartimide formation from side-

chain-protected Asp residues can be rapid, and is dependent on the side-chain-protecting group. Treatment of Asp(OBzl)-Gly, Asp(OcHex)-Gly, and Asp(O*t*Bu)-Gly with 20% piperidine-DMF for 4 h resulted in 100, 67.5, and 11% aspartimide formation, respectively (32), whereas treatment of Asp(OBzl)-Phe with 55% piperidine-DMF for 1 h resulted in 16% aspartimide formation (33). The racemization of C-terminal-esterified Cys derivatives by 20% piperidine-DMF is also problematic, with D-Cys formed to the extent of 11.8% from Cys(Trt), 9.4% from Cys(Acm), 5.9% from Cys(*t*Bu), and 36.0% from Cys(*S**t*Bu) after 4 h of treatment (34).

Some piperidine-catalyzed side-reactions may be minimized by using other bases to remove the Fmoc group. Two percent 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)-DMF, at a flow rate of 3 mL/min for 10 min, is used to minimize monodealkylation of either Tyr(PO₃Me₂) or Tyr(PO₃Bzl₂) (29). For example, 50% monodealkylation of Tyr(PO₃Me₂) occurred in 7 min with 20% piperidine-DMF, but required 5 h with 1*M* DBU in DMF, whereas 50% monodealkylation of Tyr(PO₃Bzl₂) occurred in 12 min with 20% piperidine-DMF and 14 h with 1*M* DBU in DMF (29). Racemization of esterified Cys(Trt) was reduced from 11.8% with 20% piperidine-DMF to only 2.6% with 1% DBU-DMF after 4 h of treatment (29,34). Unfortunately, aspartimide formation of Asp(O*t*Bu)-Asn is worse with DBU compared to piperidine (35). This reagent is recommended for continuous-flow syntheses only, since the dibenzofulvene intermediate does not form an adduct with DBU and thus must be washed rapidly from the peptide resin to avoid reattachment of dibenzofulvene (29). However, a solution of DBU-piperidine-DMF (1:1:48) is effective for batch syntheses, since the piperidine component scavenges the dibenzofulvene.

4. Glycopeptide Synthesis

The mild conditions of Fmoc chemistry are, in general, more suited for glycopeptide syntheses than Boc chemistry, because repetitive acid treatments can be detrimental to sugar linkages (36). However, some researchers prefer morpholine to piperidine as an Fmoc removal agent during glycopeptide SPPS, because the p*K*_a of morpholine (8.3) is lower than that of piperidine (11.1), and is thus less detrimental to side-chain glycosyls (36,37). Side-chain Ser and Thr glycosyls are stable to base deprotection by neat morpholine (38-39) for 30 min (40) and 50%

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.